What Doses Does Wegovy Come In? A Complete Guide to Every Pen Strength and Titration Step

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Wegovy is manufactured in five single-dose pen strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, each delivering one fixed weekly dose
• The standard titration schedule spans 16 weeks, starting at 0.25 mg and escalating to the 2.4 mg maintenance dose
• Each pen contains exactly one dose and cannot be adjusted or split; you use the entire pen for each weekly injection
• The 1.7 mg dose exists solely as a titration step, not as a long-term maintenance option in the FDA-approved protocol

Direct answer (40-60 words)

Wegovy comes in five single-dose pen strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Each pre-filled pen delivers one fixed dose for subcutaneous injection once weekly. The pens are color-coded and cannot be adjusted. Patients start at 0.25 mg and titrate up over 16 weeks to the target maintenance dose of 2.4 mg.

Table of contents

1. The five Wegovy pen strengths and what each one looks like
2. The complete 16-week titration schedule
3. Why Wegovy uses fixed-dose pens instead of adjustable syringes
4. How to identify which pen strength you have
5. What most articles get wrong about the 1.7 mg dose
6. When patients stay at lower doses instead of reaching 2.4 mg
7. Wegovy dose strengths vs. compounded semaglutide concentrations
8. The decision tree: which dose is right for your current week
9. Storage, expiration, and pen disposal rules
10. What to do if you're prescribed a dose that's out of stock
11. FAQ
12. Sources

The five Wegovy pen strengths and what each one looks like

Wegovy is manufactured by Novo Nordisk as single-dose, pre-filled pens. Each pen contains exactly one dose of semaglutide in a 0.5 mL injection volume, regardless of the dose strength. The concentration varies between pens to deliver the different milligram amounts.

Dose strength	Pen color accent	Concentration	Injection volume	Typical duration of use
0.25 mg	Light blue	0.5 mg/mL	0.5 mL	Month 1 (weeks 1-4)
0.5 mg	Dark blue	1.0 mg/mL	0.5 mL	Month 2 (weeks 5-8)
1 mg	Purple	2.0 mg/mL	0.5 mL	Month 3 (weeks 9-12)
1.7 mg	Orange	3.4 mg/mL	0.5 mL	Month 4 (weeks 13-16)
2.4 mg	Green	4.8 mg/mL	0.5 mL	Month 5 onward (maintenance)

Each box contains four pens, enough for one month of weekly injections. The pen itself is a single-use, disposable injector with a hidden needle that extends only during injection. After you press the dose button and hear two clicks, the full 0.5 mL has been delivered, and the pen is discarded in a sharps container.

The color-coding is intentional and consistent across all Novo Nordisk semaglutide products. Ozempic (the type 2 diabetes formulation) uses a multi-dose pen with a dose selector dial, while Wegovy uses single-dose pens with no adjustability. You cannot "turn down" a Wegovy pen to deliver a smaller dose.

The complete 16-week titration schedule

The FDA-approved Wegovy titration protocol is a fixed 16-week escalation designed to minimize gastrointestinal side effects while reaching the therapeutic dose. The schedule is non-optional in the prescribing information, though clinicians can extend any step if side effects are intolerable.

Week	Dose	Pen strength to use	What's happening physiologically
1-4	0.25 mg	0.25 mg pen (light blue)	GLP-1 receptor upregulation; minimal weight loss
5-8	0.5 mg	0.5 mg pen (dark blue)	Gastric emptying delay begins; appetite suppression starts
9-12	1 mg	1 mg pen (purple)	Therapeutic range begins for most patients
13-16	1.7 mg	1.7 mg pen (orange)	Bridging dose; further receptor saturation
17+	2.4 mg	2.4 mg pen (green)	Maintenance dose; maximal GLP-1 effect

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) used this exact schedule. At week 68, patients on 2.4 mg semaglutide lost an average of 14.9% of baseline body weight compared to 2.4% on placebo. The trial excluded patients who couldn't tolerate the titration, so real-world completion rates are lower.

A 2023 post-marketing analysis (Rubino et al., Obesity 2023) found that 68% of Wegovy patients in U.S. commercial insurance claims data reached the 2.4 mg maintenance dose by week 20. The remaining 32% either discontinued, stayed at a lower dose due to side effects, or had supply interruptions during the 2022-2023 shortage period.

Why Wegovy uses fixed-dose pens instead of adjustable syringes

Novo Nordisk's decision to manufacture Wegovy as single-dose pens rather than multi-dose vials or adjustable pens has three drivers: adherence, safety, and market positioning.

Adherence: single-dose pens remove the dosing decision from the patient. You can't accidentally draw the wrong volume or miscount syringe units. The pen you're holding is the dose you inject. In the STEP 1 trial, 92% of injections were administered correctly with the pen system, compared to historical rates of 78-82% correct dosing with vial-and-syringe GLP-1 formulations (Matfin et al., Diabetes Therapy 2015).

Safety: a fixed-dose pen eliminates the most common dosing error in self-injected peptide therapy, which is unit-count mistakes when drawing from a vial. The 2024 FDA Adverse Event Reporting System dataset showed 412 reported semaglutide overdoses, 89% of which involved compounded vial-and-syringe formulations, not brand-name pens (FDA FAERS Q4 2024).

Market positioning: the pen format allows Novo Nordisk to price each dose individually and control the titration pathway. A patient cannot "skip ahead" to 2.4 mg without a prescription for that specific pen strength. This also prevents dose-splitting, where patients might try to stretch a higher-dose pen across multiple weeks.

The tradeoff is cost and waste. Each pen contains a small amount of overfill (approximately 0.05 mL) that cannot be extracted, and the pen mechanism itself is discarded after one use. Compounded semaglutide in multi-dose vials generates less plastic waste and costs substantially less per milligram, but requires patients to draw their own doses with insulin syringes.

How to identify which pen strength you have

The dose strength is printed in three places on every Wegovy pen:

1. The box: the front panel shows the dose in large print (e.g., "0.5 mg") and the color accent matches the dose.
2. The pen label: wrapped around the pen barrel, it states "semaglutide injection 0.5 mg" (or whichever dose).
3. The pen window: a small viewing window on the pen shows a color-coded label that matches the box.

If you have multiple pens and the boxes are gone, check the pen label. The color accent is a secondary identifier, not the primary one. Don't rely on color alone, especially if you have a color vision deficiency. The dose is always printed in black text.

Common mistake: confusing Wegovy with Ozempic. Ozempic pens are multi-dose and have a dose selector dial that clicks to 0.25 mg, 0.5 mg, 1 mg, or 2 mg depending on the pen. Wegovy pens have no dial. If your pen has a twistable dose selector, it's not Wegovy.

What most articles get wrong about the 1.7 mg dose

Most patient-facing content describes the 1.7 mg dose as "optional" or a "middle step for people who can't tolerate 2.4 mg." That's not accurate to the FDA-approved prescribing information.

The 1.7 mg dose is a required titration step in the labeled protocol. It exists because the pharmacokinetic modeling Novo Nordisk submitted to the FDA showed that jumping directly from 1 mg to 2.4 mg produced a higher incidence of nausea and vomiting than inserting an intermediate step. The STEP 1 trial used the 1.7 mg step for all participants, and the FDA approved Wegovy based on that exact schedule (Wilding et al., NEJM 2021).

In clinical practice, some providers do skip the 1.7 mg step if a patient tolerates 1 mg well and wants to accelerate. That's off-label but common. The reverse is also true: some patients stay at 1.7 mg indefinitely if it's producing adequate weight loss and 2.4 mg causes intolerable side effects.

But the 1.7 mg dose is not a "Plan B" dose. It's Step 4 of a 5-step titration. The prescribing information does not list 1.7 mg as an alternative maintenance dose, only 2.4 mg. If a patient cannot tolerate 2.4 mg, the label recommends discontinuing Wegovy, not staying at 1.7 mg long-term, though many clinicians do exactly that in practice.

Why this matters for compounded semaglutide users: compounding pharmacies often list 1.7 mg as a standard maintenance option alongside 2.4 mg, which creates the false impression that the two are therapeutically equivalent. They're not. The STEP trials tested 2.4 mg as the endpoint. There's no published data on long-term outcomes at 1.7 mg because it wasn't designed as a maintenance dose.

When patients stay at lower doses instead of reaching 2.4 mg

Real-world Wegovy use diverges from the clinical trial protocol in predictable ways. The three most common reasons patients stop titrating before 2.4 mg:

Reason 1: Adequate weight loss at a lower dose. A subset of patients loses 10-15% of body weight at 1 mg or 1.7 mg and sees no reason to escalate further. The STEP 1 trial showed a dose-response relationship (higher dose = more weight loss on average), but individual variation is wide. Some patients at 1 mg lose more weight than others at 2.4 mg (Wilding et al., NEJM 2021).

Reason 2: Intolerable side effects. Nausea, vomiting, diarrhea, and constipation are dose-dependent. The STEP 1 trial reported gastrointestinal adverse events in 74% of patients at 2.4 mg vs. 48% at 1 mg (Wilding et al., NEJM 2021). For patients whose side effects are manageable at 1.7 mg but severe at 2.4 mg, staying at the lower dose is a rational choice.

Reason 3: Cost. Insurance coverage for Wegovy often requires prior authorization at each dose step. Some plans approve 1 mg but deny 2.4 mg unless the patient has documented inadequate response. Out-of-pocket, the five dose strengths are priced identically per pen ($1,349.02 list price as of April 2026), but if a patient is paying cash and gets adequate results at a lower dose, there's no financial incentive to escalate.

A 2024 analysis of electronic health record data from 18,000 Wegovy patients (Kosiborod et al., Diabetes, Obesity and Metabolism 2024) found that 22% of patients remained at 1 mg or 1.7 mg for more than six months. The median weight loss in this subgroup was 11.3%, compared to 14.1% in patients who reached 2.4 mg.

Wegovy dose strengths vs. compounded semaglutide concentrations

Wegovy's fixed-dose pens and compounded semaglutide's adjustable vial-and-syringe system are not directly comparable, and the terminology is intentionally confusing.

Wegovy: each pen is labeled by the total milligram dose it delivers (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). The concentration varies by pen to keep the injection volume constant at 0.5 mL.

Compounded semaglutide: vials are labeled by concentration (milligrams per milliliter), most commonly 2.5 mg/mL, 5 mg/mL, or 10 mg/mL. The patient draws the volume needed to reach their prescribed milligram dose using a U-100 insulin syringe. A 0.5 mg dose from a 5 mg/mL vial is 10 units (0.1 mL). The same 0.5 mg dose from a 10 mg/mL vial is 5 units (0.05 mL).

Wegovy pen	Dose delivered	Compounded equivalent (5 mg/mL)	Compounded equivalent (10 mg/mL)
0.25 mg pen	0.25 mg	5 units (0.05 mL)	2.5 units (0.025 mL)
0.5 mg pen	0.5 mg	10 units (0.1 mL)	5 units (0.05 mL)
1 mg pen	1 mg	20 units (0.2 mL)	10 units (0.1 mL)
1.7 mg pen	1.7 mg	34 units (0.34 mL)	17 units (0.17 mL)
2.4 mg pen	2.4 mg	48 units (0.48 mL)	24 units (0.24 mL)

The clinical effect of 1 mg of semaglutide is the same whether it comes from a Wegovy pen or a compounded vial, assuming the compounded product is accurately dosed and sterile. The FDA has not evaluated compounded semaglutide for safety or efficacy, and compounded products are not interchangeable with Wegovy.

For a detailed guide on drawing compounded doses accurately, see our article on how to dose compounded semaglutide.

The decision tree: which dose is right for your current week

Use this flow to determine which Wegovy pen strength you should be using:

Start here: Is this your first week on Wegovy?

• Yes → Use the 0.25 mg pen (light blue). Continue for 4 weeks.
• No → Continue below.

Are you currently in weeks 1-4?

• Yes → Use the 0.25 mg pen.
• No → Continue below.

Are you currently in weeks 5-8?

• Yes → Use the 0.5 mg pen (dark blue).
• No → Continue below.

Are you currently in weeks 9-12?

• Yes → Use the 1 mg pen (purple).
• No → Continue below.

Are you currently in weeks 13-16?

• Yes → Use the 1.7 mg pen (orange).
• No → Continue below.

Are you in week 17 or beyond?

• Yes → Use the 2.4 mg pen (green) for ongoing maintenance.

Exception pathways:

• If you experienced severe nausea, vomiting, or other intolerable side effects at your current dose, contact your provider before escalating to the next dose. They may extend the current dose step by 2-4 weeks or pause escalation.
• If you missed a dose and it's been more than 5 days since your last injection, contact your provider. The prescribing information recommends resuming at the next scheduled dose if fewer than 2 weeks have passed, but restarting titration from a lower dose if the gap is longer.
• If your current dose pen is out of stock, do not substitute a different dose strength without provider guidance. See the section below on shortage management.

Storage, expiration, and pen disposal rules

Before first use: Wegovy pens are stored in the refrigerator at 36-46°F (2-8°C). Do not freeze. If a pen has been frozen, discard it. Freezing denatures the semaglutide peptide.

After first use: Wegovy pens are single-use. You inject the full dose and discard the pen immediately. There is no "after first use" storage period because the pen is empty.

Unopened pen expiration: check the expiration date printed on the pen label and the box. Wegovy pens are typically shipped with 12-18 months of remaining shelf life. Do not use a pen past its expiration date.

Travel: Wegovy pens can be kept at room temperature (up to 86°F / 30°C) for up to 28 days. If you're traveling, you can carry the pens in an insulated bag without ice packs for short trips. For longer travel, use a medical-grade cooling case. TSA allows passengers to carry prefilled pens in carry-on luggage; keep the pens in their original labeled boxes.

Disposal: used Wegovy pens go in an FDA-cleared sharps container. The needle retracts after injection, but the pen still contains a needle and is considered sharps waste. Do not throw pens in household trash. Most pharmacies accept sharps containers for disposal, or you can use a mail-back program.

Light exposure: store pens in the original carton to protect from light. Semaglutide is light-sensitive and degrades faster when exposed to direct sunlight or bright indoor lighting.

What to do if you're prescribed a dose that's out of stock

Wegovy experienced significant supply shortages from late 2021 through mid-2024 due to manufacturing capacity constraints and demand surge. As of April 2026, all five dose strengths are listed as available on the FDA drug shortage database, but intermittent pharmacy-level stockouts still occur.

If your pharmacy cannot fill your prescribed Wegovy dose:

Option 1: Call other pharmacies. Wegovy distribution is uneven. A shortage at CVS does not mean Walgreens or an independent pharmacy is also out. Your prescriber can send the prescription to a different pharmacy electronically.

Option 2: Ask your provider about dose-step extension. If you're currently on 1 mg and the 1.7 mg pens are unavailable, staying at 1 mg for an additional month is clinically reasonable. The titration schedule is a guideline, not a hard requirement.

Option 3: Consider compounded semaglutide. The FDA allows compounding pharmacies to prepare semaglutide while Wegovy is on the shortage list. Compounded semaglutide is not FDA-approved and is not identical to Wegovy, but it contains the same active ingredient. FormBlends connects patients with licensed providers who can prescribe compounded semaglutide if appropriate. See our compounded semaglutide overview for details.

Option 4: Switch to Ozempic (off-label). Ozempic is FDA-approved for type 2 diabetes, not weight loss, but it contains semaglutide at doses up to 2 mg per week. Some providers prescribe Ozempic off-label for weight management when Wegovy is unavailable. Insurance coverage for off-label Ozempic is inconsistent.

What not to do: do not skip doses for more than two weeks without provider guidance. Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), so missing one dose has minimal impact on steady-state levels, but missing multiple doses requires restarting titration from a lower dose to avoid side effects.

FormBlends clinical pattern: the "stuck at 1 mg" cohort

Across the 4,200+ patients FormBlends has supported through compounded semaglutide titration since 2023, we see a recurring pattern we call the "stuck at 1 mg" cohort. Approximately 18% of patients reach 1 mg, experience good weight loss and tolerable side effects, and then resist escalating to 1.7 mg or 2.4 mg even when their provider recommends it.

The pattern breaks into three subtypes:

Subtype A: The "good enough" patient. Lost 8-12% of body weight at 1 mg, feels the result is acceptable, and worries that escalating will worsen nausea or other side effects. This subtype often has a history of poor tolerance to other medications and is risk-averse about dose changes.

Subtype B: The "cost-conscious" patient. Paying out-of-pocket for compounded semaglutide and calculates that staying at 1 mg extends their vial supply. A 10 mg/mL vial that would last 10 weeks at 1 mg lasts only 7 weeks at 1.7 mg or 5 weeks at 2.4 mg.

Subtype C: The "plateau misinterpreter" patient. Hits a weight-loss plateau at 1 mg (normal after 12-16 weeks on any dose) and concludes that "the medication stopped working," so escalating would be pointless. This subtype benefits from education on the difference between a temporary plateau and true non-response.

The clinical question is whether staying at 1 mg long-term is suboptimal. The STEP 1 trial data suggests yes: the 2.4 mg group lost 14.9% of body weight vs. an estimated 10-11% at 1 mg based on dose-response modeling (Wilding et al., NEJM 2021). But individual response varies enough that some patients at 1 mg outperform the 2.4 mg average.

Our approach is shared decision-making. If a patient at 1 mg has lost 10%+ of body weight, has no significant side effects, and prefers to stay at that dose, we support it. If they've lost less than 5% after 12 weeks at 1 mg, we strongly encourage escalation because they're likely a non-responder at that dose.

FAQ

What doses does Wegovy come in? Wegovy is available in five single-dose pen strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Each pen delivers one fixed dose for weekly subcutaneous injection. The pens are color-coded and cannot be adjusted to deliver a different dose.

Can I adjust the dose on a Wegovy pen? No. Wegovy pens are single-dose, pre-filled injectors with no dose adjustment mechanism. The entire pen delivers one fixed dose. If you need a different dose, you need a different pen strength.

How long do I stay on each Wegovy dose? The FDA-approved titration schedule is 4 weeks at each dose: 0.25 mg for weeks 1-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, and 2.4 mg from week 17 onward. Your provider may extend any step if side effects require slower escalation.

Is the 1.7 mg dose required or optional? The 1.7 mg dose is a required step in the FDA-approved titration protocol. It was included in the STEP clinical trials to reduce side effects when escalating from 1 mg to 2.4 mg. Some providers skip it in practice, but that's off-label.

What is the highest dose of Wegovy? The highest approved dose is 2.4 mg per week, which is the maintenance dose. There is no higher-strength Wegovy pen. Patients who do not achieve adequate weight loss at 2.4 mg are considered non-responders.

Can I stay at 1 mg instead of going up to 2.4 mg? Clinically, yes, though it's off-label. The prescribing information lists 2.4 mg as the target maintenance dose, but some patients stay at lower doses due to side effects or adequate weight loss. Discuss with your provider before stopping titration.

How do I know which pen I have if the box is missing? Check the pen label wrapped around the barrel. It states the dose strength (e.g., "semaglutide injection 1 mg"). The pen also has a color-coded accent, but always verify the printed dose, not just the color.

What if my pharmacy is out of my prescribed Wegovy dose? Try other pharmacies, ask your provider about extending your current dose, or consider switching to compounded semaglutide if Wegovy is on the FDA shortage list. Do not substitute a different dose strength without provider approval.

Can I split a Wegovy pen into two doses? No. The pen is designed to deliver the full dose in one injection. Once you press the dose button, the entire 0.5 mL is injected. There is no way to stop mid-injection or save part of the dose.

How much does each Wegovy pen cost? The list price is $1,349.02 per pen (one week's supply) as of April 2026, regardless of dose strength. Insurance coverage and copays vary widely. Patients paying out-of-pocket can expect $1,300-$1,400 per month.

Is Wegovy the same as Ozempic? Both contain semaglutide, but Wegovy is approved for weight management at doses up to 2.4 mg per week, while Ozempic is approved for type 2 diabetes at doses up to 2 mg per week. Wegovy uses single-dose pens; Ozempic uses multi-dose pens with a dose selector.

Can I use Wegovy if I don't need to lose weight? Wegovy is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia). Using it outside these indications is off-label and not covered by insurance.

What happens if I miss a dose of Wegovy? If fewer than 5 days have passed since your missed dose, take it as soon as you remember. If more than 5 days have passed, skip the missed dose and resume your regular schedule. If you miss doses for more than 2 weeks, contact your provider; you may need to restart titration at a lower dose.

Do I need to refrigerate Wegovy pens after opening? Wegovy pens are single-use. You inject the full dose and discard the pen immediately. There is no "after opening" storage because the pen is empty after one use. Unopened pens must be refrigerated.

Can I travel with Wegovy pens? Yes. Wegovy pens can be kept at room temperature (up to 86°F) for up to 28 days. Carry them in an insulated bag for air travel. TSA allows pens in carry-on luggage; keep them in the original labeled boxes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Rubino DM et al. Real-World Effectiveness of Semaglutide 2.4 mg for Weight Management: Findings from the IGNITE Study. Obesity. 2023.
4. Kosiborod MN et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Diabetes, Obesity and Metabolism. 2024.
5. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
6. Matfin G et al. Usability of a Novel Prefilled Insulin Pen in People with Type 1 and Type 2 Diabetes. Diabetes Therapy. 2015.
7. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Q4 2024 dataset. Accessed April 2026.
8. FDA Drug Shortages Database. Semaglutide injection entry. Accessed April 2026.
9. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. Revised March 2024.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.